IDEAYA Biosciences, Inc.
NASDAQ:IDYABiotechnology
-$0.45 today
- Market cap
- $2.56B
- Beta
- -0.05
- P/E (TTM)
- -19.5
- EPS (TTM)
- -$1.58
Volume 1.45M
Average 1.44M
IDYA EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
IDEAYA Biosciences, Inc.NASDAQ: IDYA
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$1.11, compared with -$0.82 a year earlier. Trailing-twelve-month EPS (Diluted) was -$1.6.
Context
- EPS (Diluted) grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 10 analysts of -$4.72 (-268.5%) for the fiscal year ending Dec 2026, a slowdown from the +61.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$1.11-18.1% QoQ
- Last fiscal yearDec 2025
- -$1.28+61.9% YoY
- LTMMar 2026
- -$1.6+55.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -35.4% | -20.1% | +15.3 pp |
| 1 year | +61.9% | -268.5% | -330.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (1.28) USD
- Year-over-year change
- +61.9%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.28) | +61.9% |
| FY2024 | 2024-12-31 | (3.36) | -71.4% |
| FY2023 | 2023-12-31 | (1.96) | -38.0% |
| FY2022 | 2022-12-31 | (1.42) | -0.7% |
| FY2021 | 2021-12-31 | (1.41) | — |
EPS (Diluted) vs competitors
How IDYA compares with its peers on the latest reported figures
- IDYA's LTM Mar 2026 EPS (Diluted) of -$1.6 is the 6th highest of the 9 companies compared; the peer median is -$1.28.
- Its year-over-year change of +55.4% is the 2nd highest of 9, against a peer median of +11.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Aug 2026 | $2.31 | +177.8% | — | |
| LTM Sep 2026 | -$0.99 | -120.0% | — | |
| LTM Mar 2026 | -$1.06 | +37.3% | — | |
| LTM Mar 2026 | -$1.17 | +14.6% | — | |
| LTM Sep 2026 | -$1.38 | -51.6% | — | |
| LTM Mar 2026 | -$1.6 | +55.4% | — | |
| LTM Jun 2026 | -$2.31 | +8.7% | — | |
| LTM Mar 2026 | -$2.73 | +23.5% | — | |
| LTM Jun 2026 | -$8.86 | -96.5% | — | |
| Peer median (excluding IDYA) | -$1.28 | +11.6% | — | |
Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.94M | 50.93M | 23.39M | 7M | 218.71M |
| Cost of Revenue | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| Gross Profit | 26.22M | 48.83M | 19.38M | 3.17M | 214.12M |
| Gross Margin | 93.8% | 95.9% | 82.9% | 45.2% | 97.9% |
| Research & Development | 58.16M | 89.54M | 129.51M | 294.67M | 314.7M |
| Selling, General & Admin | 18.33M | 21.8M | 24.3M | 35.47M | 63.32M |
| Operating Expenses | 76.48M | 111.33M | 153.81M | 330.14M | 373.43M |
| Depreciation & Amortization | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| EBITDA | (48.04M) | (56.55M) | (108.95M) | (270.64M) | (109.11M) |
| EBITDA Margin | -171.9% | -111.0% | -465.9% | -3866.3% | -49.9% |
| Operating Income | (50.27M) | (62.5M) | (134.43M) | (326.98M) | (159.31M) |
| Operating Margin | -179.9% | -122.7% | -574.9% | -4671.1% | -72.8% |
| Interest Income | 506K | 3.85M | 21.47M | 52.5M | 45.62M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 506K | 3.85M | 21.47M | 52.5M | 45.62M |
| Income Before Tax | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Pre-Tax Margin | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Net Margin | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| EPS (Basic) | (1.41) | (1.42) | (1.96) | (3.36) | (1.28) |
| EPS (Diluted) | (1.41) | (1.42) | (1.96) | (3.36) | (1.28) |
| Weighted Avg Shares | 35.25M | 41.44M | 57.52M | 81.68M | 88.49M |
| Weighted Avg Shares (Diluted) | 35.25M | 41.44M | 57.52M | 81.68M | 88.49M |
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
Intrinsic Alpha fair value
Locked
Current Price
$26.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.